CARBOGEN AMCIS Shanghai Achieves Zero-Deficiency Result in Unannounced NMPA GMP Inspection

A zero-deficiency outcome from an unannounced regulatory audit is the clearest signal a CDMO can send to prospective partners about the operational state of its quality systems. CARBOGEN AMCIS confirmed on 9 May 2026 that its Shanghai facility passed an unannounced NMPA GMP inspection conducted on 14 April 2026 with no deficiencies requiring formal response, alongside advisory recommendations for continuous improvement.

NMPA inspectors assessed API manufacturing operations, process controls, the quality control laboratory, documentation practices, and the facility's overall quality management system during the single-day unannounced visit. The scope reflects the breadth of scrutiny applied under China's current GMP framework, which aligns progressively with ICH Q10 principles on pharmaceutical quality systems. No corrective action obligations were issued at inspection close.

For QA directors and plant heads evaluating CDMO partnerships in the China market, the unannounced nature of the inspection carries specific weight. Routine readiness programs that perform under scheduled audit conditions do not always translate to consistent GMP execution in daily operations; an unannounced inspection removes that variable. Site Quality Head Simone Maggi noted that the result confirms GMP consistency across the facility under normal operating conditions, not a prepared state.

The Shanghai site functions as an API manufacturing and process development node within CARBOGEN AMCIS's global network, which operates under the Dishman Carbogen Amcis Limited parent structure headquartered in Ahmedabad, India. Regulatory acceptance of the Shanghai facility by NMPA supports the site's positioning for both domestic Chinese market supply and international technology transfer programs where Chinese regulatory standing is a contractual prerequisite.

Vice President of Quality and Compliance Stephanie Schlienger attributed the outcome to the maturity of the site's quality system and the preparedness level of the local team, framing the result as consistent with the company's stated commitment to GMP standards across all operational stages.

The advisory recommendations issued during the inspection, while not classified as deficiencies, represent a documented input into the facility's CAPA pipeline and will serve as a measurable benchmark against which the next inspection cycle can be assessed.

Source: CARBOGEN AMCIS Innovations AG via GlobeNewswire, 9 May 2026.